Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B

Scherrer, Alexandra UAlexandra UScherrerLedergerber, BrunoBrunoLedergerbervon Wyl, ViktorViktorvon WylBöni, JürgJürgBöniYerly, SabineSabineYerlyKlimkait, ThomasThomasKlimkaitBürgisser, PhilippePhilippeBürgisserRauch, AndriAndriRauch0000-0001-5297-6062Hirschel, BernardBernardHirschelCavassini, MatthiasMatthiasCavassiniElzi, LuigiaLuigiaElziVernazza, Pietro LPietro LVernazzaBernasconi, EnosEnosBernasconiHeld, LeonhardLeonhardHeldGünthard, Huldrych FHuldrych FGünthardSwiss HIV Cohort, StudyStudySwiss HIV Cohort2024-10-112024-10-112011https://boris-portal.unibe.ch/handle/20.500.12422/78691Antiretroviral compounds have been predominantly studied in human immunodeficiency virus type 1 (HIV-1) subtype B, but only ~10% of infections worldwide are caused by this subtype. The analysis of the impact of different HIV subtypes on treatment outcome is important.enImproved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype Barticle10.7892/boris.82652199828400029727990002010.1093/cid/cir669